tradingkey.logo

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

ReutersApr 7, 2025 8:10 PM

- Savara Inc SVRA.O:

  • SAVARA ANNOUNCES ENCORE PRESENTATIONS FROM THE PHASE 3 IMPALA-2 TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT TWO UPCOMING SCIENTIFIC CONFERENCES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI